Cargando…

In vivo Detection of Alzheimer’s Disease

Recent revisions to the diagnostic criteria for Alzheimer’s disease (AD) incorporated conceptual advances in the field. Specifically, AD is now recognized to encompass a continuum, spanning from preclinical (accruing brain pathology in the absence of symptoms) through symptomatic predementia (prodro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leuzy, Antoine, Heurling, Kerstin, Ashton, Nicholas J., Schöll, Michael, Zimmer, Eduardo R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	YJBM 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153625/ https://www.ncbi.nlm.nih.gov/pubmed/30258316

Ejemplares similares

Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
por: Zimmer, Eduardo Rigon, et al.
Publicado: (2014)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals
por: Zimmer, Eduardo Rigon, et al.
Publicado: (2014)

Imaging Alzheimer's disease pathophysiology with PET
por: Schilling, Lucas Porcello, et al.
Publicado: (2016)

Cognitive Intervention As an Early Non-pharmacological Strategy in Alzheimer's Disease: A Translational Perspective
por: Gehres, Sarah W., et al.
Publicado: (2016)

Blood‐based biomarkers for Alzheimer's disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
por: Simrén, Joel, et al.
Publicado: (2021)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

The implications of different approaches to define AT(N) in Alzheimer disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone
por: R Zimmer, Eduardo, et al.
Publicado: (2015)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948
por: Smith, Ruben, et al.
Publicado: (2019)

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy
por: Grothe, Michel J., et al.
Publicado: (2021)

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
por: Cullen, Nicholas C., et al.
Publicado: (2021)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer’s disease, subjects with amnestic mild cognitive impairment and healthy volunteers
por: Miki, Takami, et al.
Publicado: (2017)

Biomarkers for Microglial Activation in Alzheimer's Disease
por: Lautner, Ronald, et al.
Publicado: (2011)

In vivo molecular imaging of neuroinflammation in Alzheimer's disease
por: Chaney, Aisling, et al.
Publicado: (2018)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

In Vivo TSPO Signal and Neuroinflammation in Alzheimer’s Disease
por: Tournier, Benjamin B., et al.
Publicado: (2020)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease
por: Johansson, Maurits, et al.
Publicado: (2021)

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease
por: Yap, Steven Y, et al.
Publicado: (2021)

Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography
por: Schöll, Michael, et al.
Publicado: (2015)

Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease
por: Veitch, Dallas P., et al.
Publicado: (2021)

A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease
por: Brum, Wagner S., et al.
Publicado: (2022)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
por: Boccardi, Marina, et al.
Publicado: (2021)

[(18)F]FDG PET signal is driven by astroglial glutamate transport
por: Zimmer, Eduardo R., et al.
Publicado: (2017)

The Impact of Cholesterol, DHA, and Sphingolipids on Alzheimer's Disease
por: Grimm, Marcus O. W., et al.
Publicado: (2013)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
por: Leuzy, Antoine, et al.
Publicado: (2023)

A Novel Ex Vivo Model to Investigate the Underlying Mechanisms in Alzheimer’s Disease
por: Brai, Emanuele, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d9g2c11itd3vp5ieud6jrhidk4